Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.78 |
| ▸ | TSHR | P16473 | 1/20 | 0.78 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.78 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.78 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.78 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | PTGER4 | P35408 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lonidamine SCHEMBL29351122 | 0.88 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6CYP2C9TSHR | |
| Xinidamine SCHEMBL2110578 | 0.88 | CYP1A2 (0.63) | CYP1A2CYP3A4CYP2D6CYP2C9TSHR | |
| Lonidamine SCHEMBL7134 | 0.88 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6CYP2C9TSHR | |
| Lonidamine SCHEMBL29350056 | 0.88 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL14595157 | 0.87 | CYP1A2 (0.60) | CYP1A2CYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL12787875 | 0.87 | CYP1A2 (0.60) | CYP1A2CYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL1603908 | 0.86 | CYP1A2 (0.59) | CYP1A2CYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL5437117 | 0.85 | CYP1A2 (0.58) | CYP1A2CYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL14584151 | 0.85 | CYP1A2 (0.82) | CYP1A2CYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL14584144 | 0.85 | CYP1A2 (0.73) | CYP1A2CYP3A4CYP2D6CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250269031-A1 | MITOCHONDRIA TARGETING QUINOLINIUM-DRUG CONJUGATES AND THEIR SELF-ASSEMBLING NANOFORMULATIONS FOR CANCER THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-08-28 | — | — | US | claimed |
| WO-2022115443-A1 | MITOCHONDRIA TARGETING QUINOLINIUM-DRUG CONJUGATES AND THEIR SELF-ASSEMBLING NANOFORMULATIONS FOR CANCER THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-06-02 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1610778-A4 | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | THRESHOLD PHARMACEUTICALS INC (US) | 2006-05-31 | — | — | EP | claimed |
| CN-1738616-A | Combination therapies for the treatment of cancer | THRESHOLD PHARMACEUTICALS INC (US) | 2006-02-22 | — | — | CN | claimed |
| EP-1610778-A2 | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | Threshold Pharmaceuticals, Inc. (US) | 2006-01-04 | — | — | EP | claimed |
| US-20050272795-A1 | Prevention and treatment of benign prostatic hyperplasia | THRESHOLD PHARMACEUTICALS, INC. (US) | 2005-12-08 | — | — | US | claimed |
| WO-2004064735-A2 | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | THRESHOLD PHARMACEUTICALS, INC. (US) | 2004-08-05 | — | — | WO | claimed |
| EP-3990433-B1 | PROCESSES OF MAKING 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES | TRANSLATUM MEDICUS INC (CA) | 2026-05-20 | — | — | EP | disclosed |
| US-20250269031-A1 | MITOCHONDRIA TARGETING QUINOLINIUM-DRUG CONJUGATES AND THEIR SELF-ASSEMBLING NANOFORMULATIONS FOR CANCER THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-08-28 | — | — | US | disclosed |
| US-12122751-B2 | Processes of making 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives | Translatum Medicus Inc. (CA) | 2024-10-22 | — | — | US | disclosed |
| US-20240025859-A1 | PROCESSES OF MAKING 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES | Translatum Medicus Inc. (CA) | 2024-01-25 | — | — | US | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272795-A1 | Prevention and treatment of benign prostatic hyperplasia | BPHL, LPXN, QDPR | CYP1A2 1175/4885CYP3A4 1278/4885CYP2D6 1446/4885 |
| US-12122751-B2 | Processes of making 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives | PCMT1, ICMT, FNTA | CYP1A2 594/4885CYP3A4 608/4885CYP2D6 956/4885 |
| US-20240025859-A1 | PROCESSES OF MAKING 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES | PCMT1, ICMT, FNTA | CYP1A2 594/4885CYP3A4 608/4885CYP2D6 956/4885 |
| US-20250269031-A1 | MITOCHONDRIA TARGETING QUINOLINIUM-DRUG CONJUGATES AND THEIR SELF-ASSEMBLING NANOFORMULATIONS FOR CANCER THERAPY | MFN2, UQCRC2, UQCRC1 | CYP1A2 1333/4885CYP3A4 805/4885CYP2D6 603/4885 |
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | CYP1A2 4880/4885CYP3A4 4863/4885CYP2D6 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.